Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis Journal Article


Authors: Gao, T.; Ptashkin, R.; Bolton, K. L.; Sirenko, M.; Fong, C.; Spitzer, B.; Menghrajani, K.; Arango Ossa, J. E.; Zhou, Y.; Bernard, E.; Levine, M.; Medina Martinez, J. S.; Zhang, Y.; Franch-Expósito, S.; Patel, M.; Braunstein, L. Z.; Kelly, D.; Yabe, M.; Benayed, R.; Caltabellotta, N. M.; Philip, J.; Paraiso, E.; Mantha, S.; Solit, D. B.; Diaz, L. A. Jr; Berger, M. F.; Klimek, V.; Levine, R. L.; Zehir, A.; Devlin, S. M.; Papaemmanuil, E.
Article Title: Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
Abstract: Stably acquired mutations in hematopoietic cells represent substrates of selection that may lead to clonal hematopoiesis (CH), a common state in cancer patients that is associated with a heightened risk of leukemia development. Owing to technical and sample size limitations, most CH studies have characterized gene mutations or mosaic chromosomal alterations (mCAs) individually. Here we leverage peripheral blood sequencing data from 32,442 cancer patients to jointly characterize gene mutations (n = 14,789) and mCAs (n = 383) in CH. Recurrent composite genotypes resembling known genetic interactions in leukemia genomes underlie 23% of all detected autosomal alterations, indicating that these selection mechanisms are operative early in clonal evolution. CH with composite genotypes defines a patient group at high risk of leukemia progression (3-year cumulative incidence 14.6%, CI: 7–22%). Multivariable analysis identifies mCA as an independent risk factor for leukemia development (HR = 14, 95% CI: 6–33, P < 0.001). Our results suggest that mCA should be considered in conjunction with gene mutations in the surveillance of patients at risk of hematologic neoplasms. © 2021, The Author(s).
Keywords: mutation; genetic analysis; chromosome; gene expression; genotype; risk factor; physiological response; cell component; cancer
Journal Title: Nature Communications
Volume: 12
ISSN: 2041-1723
Publisher: Nature Publishing Group  
Date Published: 2021-01-12
Start Page: 338
Language: English
DOI: 10.1038/s41467-020-20565-7
PROVIDER: scopus
PMCID: PMC7804935
PUBMED: 33436578
DOI/URL:
Notes: Article -- Export Date: 1 February 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Virginia Klimek
    147 Klimek
  2. David Solit
    778 Solit
  3. Ross Levine
    775 Levine
  4. Ahmet Zehir
    343 Zehir
  5. Michael Forman Berger
    764 Berger
  6. Barbara Spitzer
    78 Spitzer
  7. Minal A Patel
    70 Patel
  8. Sean McCarthy Devlin
    601 Devlin
  9. John Philip
    48 Philip
  10. Simon H Mantha
    67 Mantha
  11. Rym Benayed
    188 Benayed
  12. Daniel William Kelly
    29 Kelly
  13. Mariko   Yabe
    50 Yabe
  14. Yanming Zhang
    199 Zhang
  15. Elsa Bernard
    49 Bernard
  16. Luis Alberto Diaz
    148 Diaz
  17. Juan Santiago Medina
    37 Medina
  18. Maria Sirenko
    13 Sirenko
  19. Kelly Leigh Bolton
    35 Bolton
  20. Max Levine
    33 Levine
  21. Christopher Joseph Fong
    42 Fong
  22. Yangyu Zhou
    14 Zhou
  23. Teng Gao
    12 Gao